MIA Reports

MIA's Gavin Crowell-Williamson interviews PharmedOut founder Dr. Adriane Fugh-Berman about Big Pharma's influence on medical education.

The ACE study tells of how adverse childhood experiences increase the risk of psychological and physical problems in adulthood. When will we start incorporating these findings into public health policy and medical care?

MIA's Peter Simons interviews David Cohen, PhD, on his path to researching mental health, coercive practices, and discontinuation from psychiatric drugs.

Akansha Vaswani interviews Dr. John Read about the influences on his work and his research on madness, psychosis, and the mental health industry.

The New Yorker's story on Laura Delano and psychiatric drug withdrawal is a glass-half-full story: It addresses a problem in psychiatry and yet hides the deeper story to be told. A story of how her recovery resulted from seeing herself within a counter-narrative that tells of the harm that psychiatry can do.

Dr. Raskin discusses psychotherapists’ dissatisfaction with current psychiatric diagnostic systems and explores alternatives.

Author William Styron is often remembered for speaking about depression as an illness. But a review of his life reveals that psychiatric drugs may have triggered and even worsened his depressive episodes.

Dr. Vance Trudeau discusses his study's finding that antidepressants may have far-reaching, adverse effects that last up to three generations.

In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.

Dr. Gail Hornstein, author of Agnes’s Jacket: A Psychologist’s Search for the Meanings of Madness, discusses the importance of personal narratives and service-user activism in the context of the global mental health movement.

In a MIA survey of people who had been patients in mental hospitals, nearly 500 respondents told of an experience that was often traumatic, and frequently characterized by a violation of their legal rights, forced treatment with drugs, and physical or sexual abuse. Only 17% said they were “satisfied” with the “quality of the psychiatric treatment” they received.

STAT recently published an opinion piece arguing that the black box warning on antidepressants has led to an increase in adolescent suicide. It is easily debunked, and reveals once again how our society is regularly misled about research findings related to psychiatric drugs. STAT has lent its good name to a false story that, unfortunately, will resonate loudly with the public.

During the past twenty years, the American Foundation for Suicide Prevention and American psychiatry have adopted a "medicalized" approach to preventing suicide, claiming that antidepressants are protective against suicide. Yet, the suicide rate in the United States has increased 30% since 2000, a time of rising usage of antidepressants. A review of studies of the effects of mental health treatment and antidepressants on suicide reveals why this medicalized approach has not only failed, but pushed suicide rates higher.

After a meta-analysis of RCTs of antidepressants was published in Lancet, psychiatry stated that it proved that "antidepressants" work. However, effectiveness studies of real-world patients reveal the opposite: the medications increase the likelihood that patients will become chronically depressed, and disabled by the disorder.

In Israel, there is a budding Soteria movement that foretells of a possible paradigm shift in care. The thought is that such care may become a first-line treatment for newly psychotic patients.

The published report of the Broaden Trial of Deep Brain Stimulation for Depression whitewashed the results: although the efficacy results were negative, the investigators concluded that the therapy still showed "promise", and adverse events suffered by the patients were downplayed or attributed to the disease, and not the treatment. An in-depth investigation of how the trial results were spun, and interviews with patients that tell of harm done.

Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.

Lancet Psychiatry, a UK-based medical journal, recently published a study that concluded brain scans showed that individuals diagnosed with ADHD had smaller brains. That conclusion is belied by the study data. The journal needs to retract this study. UPDATE: Lancet Psychiatry (online) has published letters critical of the study, and the authors' response, and a correction.

The Ministry of Health in Norway has ordered its four regional health authorities to offer medicine-free treatment in psychiatric hospitals. A six-bed ward in Tromso, which is in the far north of Norway, is now providing such care.

When Carina Håkansson sent out an invitation for a symposium on "Pharmaceuticals: Risks and Alternatives," some of the world's top scientists, along with experts-by-experience, came from 13 countries to explore better ways to respond to people in crisis.

Tony Kendrick, a professor of Primary Care at the University of Southampton, has found through his research and practice that too many people are being prescribed antidepressants long-term without the information and support necessary to get off of them.

This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.

Researchers, Jon Jureidini, Jay Amsterdam and Leemon McHenry, have taken a closer look at the data from a randomized control trial of citalopram (Celexa) that was ghostwritten and then used by the manufacturers to support claims of the drug’s efficacy and safety in the treatment of child and adolescent depression. To get the background on this story, we connected with Dr. Leemon McHenry, an investigator in this study and a lecturer in philosophy at California State University, Northridge.

In the past five years, there has been a dramatic explosion of interest in the Open Dialogue Therapy practiced in Tornio, Finland. It is a humanistic “treatment” that has produced five-year outcomes for psychotic patients that are, by far, the best in the developed world, and there are now groups in the United States, Europe and beyond that are seeking to “import” this care. However, the challenges for doing so are many and, last month, Open Dialogue UK - on the occasion of the first-ever fully recognized Open Dialogue training outside of Tornio - organized a conference in London to hold an open dialogue about Open Dialogue.

Hundreds of people have been given remote control deep brain stimulation implants for psychiatric disorders such as depression, OCD and Tourette’s. Yet DBS specialists still have no clue about its mechanisms of action and research suggests its hefty health and safety risks far outweigh benefits.